Logo image of BJDX

BLUEJAY DIAGNOSTICS INC (BJDX) Stock Fundamental Analysis

NASDAQ:BJDX - Nasdaq - US0956335097 - Common Stock - Currency: USD

1.91  -0.02 (-1.04%)

After market: 2.0275 +0.12 (+6.15%)

Fundamental Rating

2

Taking everything into account, BJDX scores 2 out of 10 in our fundamental rating. BJDX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. BJDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BJDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BJDX has reported negative net income.
BJDX had a negative operating cash flow in the past year.
BJDX had negative earnings in each of the past 5 years.
BJDX had a negative operating cash flow in each of the past 5 years.
BJDX Yearly Net Income VS EBIT VS OCF VS FCFBJDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

BJDX has a Return On Assets of -86.62%. This is in the lower half of the industry: BJDX underperforms 78.84% of its industry peers.
Looking at the Return On Equity, with a value of -108.86%, BJDX is doing worse than 62.96% of the companies in the same industry.
Industry RankSector Rank
ROA -86.62%
ROE -108.86%
ROIC N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BJDX Yearly ROA, ROE, ROICBJDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

BJDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BJDX Yearly Profit, Operating, Gross MarginsBJDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

BJDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BJDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BJDX has less shares outstanding
Compared to 1 year ago, BJDX has an improved debt to assets ratio.
BJDX Yearly Shares OutstandingBJDX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
BJDX Yearly Total Debt VS Total AssetsBJDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

BJDX has an Altman-Z score of -5.30. This is a bad value and indicates that BJDX is not financially healthy and even has some risk of bankruptcy.
BJDX's Altman-Z score of -5.30 is on the low side compared to the rest of the industry. BJDX is outperformed by 70.37% of its industry peers.
BJDX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
BJDX's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. BJDX outperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -5.3
ROIC/WACCN/A
WACC9.08%
BJDX Yearly LT Debt VS Equity VS FCFBJDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 4.38 indicates that BJDX has no problem at all paying its short term obligations.
BJDX's Current ratio of 4.38 is fine compared to the rest of the industry. BJDX outperforms 68.25% of its industry peers.
BJDX has a Quick Ratio of 4.38. This indicates that BJDX is financially healthy and has no problem in meeting its short term obligations.
BJDX has a Quick ratio of 4.38. This is in the better half of the industry: BJDX outperforms 74.60% of its industry peers.
Industry RankSector Rank
Current Ratio 4.38
Quick Ratio 4.38
BJDX Yearly Current Assets VS Current LiabilitesBJDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BJDX have decreased strongly by -13142.79% in the last year.
EPS 1Y (TTM)-13142.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9218.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BJDX will show a very strong growth in Earnings Per Share. The EPS will grow by 30.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BJDX Yearly Revenue VS EstimatesBJDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2025 2026 2M 4M 6M 8M
BJDX Yearly EPS VS EstimatesBJDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BJDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BJDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BJDX Price Earnings VS Forward Price EarningsBJDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BJDX Per share dataBJDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K

4.3 Compensation for Growth

A more expensive valuation may be justified as BJDX's earnings are expected to grow with 30.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.65%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BJDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEJAY DIAGNOSTICS INC

NASDAQ:BJDX (5/20/2025, 8:00:01 PM)

After market: 2.0275 +0.12 (+6.15%)

1.91

-0.02 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)N/A N/A
Inst Owners1.71%
Inst Owner Change0.1%
Ins Owners0.11%
Ins Owner Change0%
Market Cap2.85M
Analysts43.33
Price TargetN/A
Short Float %7.7%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-1395.79
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-5.72
FCFYN/A
OCF(TTM)-5.41
OCFYN/A
SpS0
BVpS5.8
TBVpS5.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.62%
ROE -108.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 121.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.38
Quick Ratio 4.38
Altman-Z -5.3
F-Score6
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)331.42%
Cap/Depr(5y)201.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13142.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9218.18%
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.46%
OCF growth 3YN/A
OCF growth 5YN/A